AT Shaw, TM Bauer, F de Marinis, E Felip… - … England Journal of …, 2020 - Mass Medical Soc
Background Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK),
has antitumor activity in previously treated patients with ALK-positive non–small-cell lung …